GSK plc vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
6.3
Neutral
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
GSK
High-quality business with 41% return on equity and 18% profit margins.
⚠ cautious analyst consensus — few Buy ratings.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
HOLD
Target $57.65 (+11.7%)
8 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
GSK
MRK
13.4×
Trailing P/E
31.5×
9.9×
Forward P/E
11.5×
17.8%
Profit Margin
13.6%
72.9%
Gross Margin
76.6%
40.9%
ROE
—
1.5%
Revenue Growth
4.9%
8.4%
Earnings Growth
—
0.35
Beta
0.28
—
Price / Book
—
$103.0B
Market Cap
$277.0B
$35 – $62
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →